PCM
CLVS

Price Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Price Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,078
Closed -$228K – 233
2015
Q1 		$228K Buy
+3,078
New +$217K 0.14% 242

Other funds holding CLVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return

Price Capital Management's CLVS Position: Q2 2015 in Review

Price Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2015, closing a stake of 3,078 shares — an estimated $228K sold.

Price Capital Management first reported a position in CLVS in Q1 2015 and held it in 1 quarter. The position peaked at $228K in Q1 2015. 176 funds tracked by Wall St. Rank hold CLVS as of Q2 2015.

  • Price Capital Management reported no remaining Clovis Oncology, Inc. position as of Q2 2015 after selling out during the quarter.
  • Price Capital Management sold 3,078 Clovis Oncology, Inc. shares in Q2 2015, an estimated $228K.
  • Price Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 1 quarter.
  • Price Capital Management's Clovis Oncology, Inc. position peaked at $228K in Q1 2015.
  • 176 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2015.

Based on Price Capital Management's 13F filing for Q2 2015.